# Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

> **NCT02049385** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 10 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Diazoxide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02049385
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-03
- **Primary completion:** 2016-07-21
- **Final completion:** 2016-07-21
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Severe side effects \& lack of target engagement
- **Last updated:** 2017-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049385, "Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02049385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*